Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-05-08 2:22 pm Sale |
2024-04-30 | 13G | UroGen Pharma Ltd. URGN |
BlackRock Inc. BLK |
1,669,543 4.600% |
-49,761 (-2.89%) |
Filing |
| 2024-02-22 09:23 am Unchanged |
2023-07-28 | 13D | UroGen Pharma Ltd. URGN |
Moshe Arkin | 1,369,315 4.440% |
0 (Unchanged) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | UroGen Pharma Ltd. URGN |
RA CAPITAL MANAGEMENT L.P. | 3,083,558 9.990% |
8 (+0.00%) |
Filing History |
| 2024-02-14 4:38 pm Unchanged |
2023-12-31 | 13G | UroGen Pharma Ltd. URGN |
Great Point Partners, LLC | 2,620,545 8.490% |
0 (Unchanged) |
Filing History |
| 2024-02-14 10:02 am Sale |
2023-12-31 | 13G | UroGen Pharma Ltd. URGN |
MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 7.460% |
-615,971 (-21.10%) |
Filing History |
| 2024-02-14 10:01 am Sale |
2023-12-31 | 13G | UroGen Pharma Ltd. URGN |
Stonepine Capital Management, LLC | 0 0.000% |
-1,304,947 (Position Closed) |
Filing History |
| 2024-02-14 07:07 am Purchase |
2023-12-31 | 13G | UroGen Pharma Ltd. URGN |
RTW Investments, LP | 1,726,808 5.600% |
1,726,808 (New Position) |
Filing History |
| 2024-02-02 2:18 pm Purchase |
2023-12-31 | 13G | UroGen Pharma Ltd. URGN |
BlackRock Inc. BLK |
1,719,304 5.600% |
1,378,892 (+405.07%) |
Filing |
| 2023-12-29 4:30 pm Purchase |
2023-12-19 | 13G | UroGen Pharma Ltd. URGN |
RA CAPITAL MANAGEMENT L.P. | 3,083,550 9.990% |
3,083,550 (New Position) |
Filing History |
| 2023-09-15 1:39 pm Purchase |
2023-09-08 | 13G | UroGen Pharma Ltd. URGN |
Great Point Partners, LLC | 2,620,545 8.510% |
2,620,545 (New Position) |
Filing History |
| 2023-08-04 08:56 am Purchase |
2023-07-26 | 13D | UroGen Pharma Ltd. URGN |
Monograph Capital Holdings Advisors, LLC | 1,662,327 5.400% |
1,662,327 (New Position) |
Filing History |
| 2023-06-12 08:47 am Sale |
2023-06-12 | 13G | UroGen Pharma Ltd. URGN |
MENORA MIVTACHIM HOLDINGS LTD. | 2,919,002 12.450% |
-35,697 (-1.21%) |
Filing History |
| 2023-02-13 10:57 am Purchase |
2022-12-31 | 13G | UroGen Pharma Ltd. URGN |
Stonepine Capital Management, LLC | 1,304,947 5.700% |
108,039 (+9.03%) |
Filing History |
| 2022-12-02 11:15 am Purchase |
2022-11-22 | 13G | UroGen Pharma Ltd. URGN |
Stonepine Capital Management, LLC | 1,196,908 5.200% |
1,196,908 (New Position) |
Filing History |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | UroGen Pharma Ltd. URGN |
BlackRock Inc. BLK |
340,412 1.500% |
-1,387,682 (-80.30%) |
Filing |
| 2022-02-14 4:15 pm Sale |
2021-12-31 | 13G | UroGen Pharma Ltd. URGN |
Wildcat Capital Management LLC | 533,139 2.400% |
-719,146 (-57.43%) |
Filing History |
| 2022-02-14 1:44 pm Sale |
2021-12-31 | 13G | UroGen Pharma Ltd. URGN |
CREDIT SUISSE AG | 1,085,749 4.840% |
-35,322 (-3.15%) |
Filing History |
| 2022-02-04 09:12 am Sale |
2021-12-31 | 13G | UroGen Pharma Ltd. URGN |
Wellington Management Group LLP | 238,008 1.060% |
-1,602,629 (-87.07%) |
Filing History |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | UroGen Pharma Ltd. URGN |
BlackRock Inc. BLK |
1,728,094 7.700% |
198,603 (+12.98%) |
Filing |
| 2021-02-12 4:10 pm Purchase |
2020-12-31 | 13G | UroGen Pharma Ltd. URGN |
Wildcat Capital Management LLC | 1,252,285 5.670% |
96,423 (+8.34%) |
Filing History |